Light Science Technologies Holdings PLC

Light Science Technologies CEO Simon Deacon said the Injectaclad acquisition has helped drive the company's quoted pipeline to over £50 million, with more than £20 million tied to passive fire protection. Since the April deal, the company has secured orders and projects worth between £1.28 million and £1.66 million, with order volumes exceeding expectations and integration progressing well. Deacon noted that owning both the product and installation capability allows the company to engage with projects at the grassroots level, improving conversion of opportunities across a market where over 40,000 buildings require fire safety remediation. Beyond fire protection, the company has completed a Nottingham Trent University AgTech project, started another, and won over 14 new clients in its contract electronics business.

Tower Resources has raised £400,000 to bolster working capital while it waits on government approvals in Namibia and Cameroon, with both farm-out deals potentially completing as early as July. Buccaneer Energy reported an 18% rise in proved reserves in an independent review tied to its bank credit facility, with the borrowing base confirmed at $4.45 million and more growth expected as production ramps up. Light Science Technologies secured up to £1.66 million in orders for its passive fire protection division since April's RLUK Injection acquisition, becoming a vertically integrated business spanning installation and material supply. Eco Buildings Group has started building a second-generation AI-enabled manufacturing line in Albania, the first major use of its recent £2.35 million fundraise, with the new line expected to be operational by the fourth quarter. Fieldwork Robotics, backed by Frontier IP Group, picked up a £300,000 investment from SEED Innovations to roll out its soft fruit harvesting robots, with multi-robot fleets potentially on farms from 2027 if trials succeed. ImmuPharma flagged new research suggesting its lead drug candidate could help treat glioblastoma, an aggressive brain cancer, while its main focus remains autoimmune disease.